{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T16:58:47.710002",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 64,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS; time from randomisation to death from any cause)",
        "overall survival (OS)",
        "overall survival",
        "survival advantage",
        "progression-free survival (PFS; RECIST 1.1; time from randomisation until disease progression or death from any cause)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (independent review panel; RECIST 1.1)",
        "progression-free survival (PFS)",
        "progression-free survival",
        "prolonged progression-free survival",
        "event-free survival",
        "time to progression",
        "time to next treatment",
        "duration of treatment",
        "dropout rate",
        "mortality-related toxicity",
        "morbidity and mortality associated with clinical events"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1, blinded independent central review)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR)",
        "overall response rate",
        "response rate",
        "response rates",
        "complete response (RECIST 1.1)",
        "complete response (RECIST 1.1 criteria)",
        "partial response (RECIST 1.1)",
        "partial response (RECIST 1.1 criteria)",
        "disease control rate",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "duration of response",
        "time to response"
      ],
      "progression_measures": [
        "dose modifications",
        "time to deterioration of overall health status",
        "time to deterioration of physical functioning",
        "symptom control",
        "physical benefits",
        "psychological benefits",
        "preservation of quality of life"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (AEs; total)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (Common Terminology Criteria for Adverse Events, CTCAE v5.0)",
        "adverse events (general)",
        "adverse events",
        "side effects (PRO-CTCAE instrument)",
        "serious side effects on the skin",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "adverse events grade ≥3",
        "grade 3 or higher adverse events",
        "serious adverse events (grade 3-4)",
        "severe adverse events",
        "severe adverse events (interstitial lung disease)",
        "liver disorders (severe AE)",
        "stomatitis (AE)",
        "peripheral oedema (AE)",
        "peripheral neuropathy (AE)",
        "alopecia (AE)",
        "blood and lymphatic system disorders (AE)",
        "fatigue (AE)",
        "fatigue",
        "fever (AE)",
        "fever",
        "infections and infestations (AE)",
        "chest pain",
        "dyspnoea",
        "cough",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia",
        "treatment discontinuation due to adverse events",
        "discontinuation due to adverse events",
        "adverse event rate"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "adverse events grade ≥3",
        "grade 3 or higher adverse events",
        "severe adverse events",
        "mortality-related toxicity",
        "morbidity and mortality associated with clinical events"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events",
        "discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "item GP5 of the FACT-G",
        "PGI-C",
        "PGIC",
        "PGIS",
        "NSCLC-SAQ",
        "PRO-CTCAE",
        "EQ-5D-5L",
        "EQ-5D VAS",
        "visual analogue scale",
        "health-related quality of life (EORTC QLQ-C30 functional scales)",
        "health-related quality of life (measured by time to death)"
      ],
      "functional_status": [
        "physical functioning",
        "overall health status",
        "time to deterioration of overall health status",
        "time to deterioration of physical functioning"
      ],
      "symptom_measures": [
        "symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C)",
        "symptom control"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "disutility for intravenous administration",
        "time-to-death utilities",
        "health-state utilities"
      ],
      "resource_utilization": [
        "duration of treatment"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "dose modifications"
      ],
      "biomarkers": []
    }
  }
}